General, Melanoma, Non-small cell lung cancer (NSCLC)
other systemic therapies
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA203 product.
MANUFACTURING: IMA203 product will be made from the patient's white blood cells.
TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203 product infusion to improve the duration of time that IMA203 product stays in the body. The patient will be admitted to the hospital during the treatment.
After the IMA203 product infusion, a low dose of IL-2 will be given subcutaneously twice daily for 14 days.
Since this study involves gene therapy, patients will be monitored throughout the study and for up to a total of 15 years.
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA203 product.
MANUFACTURING: IMA203 product will be made from the patient's white blood cells.
TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203 product infusion to improve the duration of time that IMA203 product stays in the body. The patient will be admitted to the hospital during the treatment.
After the IMA203 product infusion, a low dose of IL-2 will be given subcutaneously twice daily for 14 days.
Since this study involves gene therapy, patients will be monitored throughout the study and for up to a total of 15 years.
